T1	Participants 630 968	Participants (aged 18-65 years) were randomly assigned (2:2:1), via two computer-generated randomisation lists for individuals potentially deployed in endemic areas and those not deployed, to receive a single intramuscular dose of high-dose vaccine (5 × 10(10) viral particles), low-dose vaccine (2·5 × 10(10) viral particles), or placebo
T2	Participants 565 628	Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
T3	Participants 970 1033	Deployed participants were allocated to only the vaccine groups
T4	Participants 1608 1812	22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo (n=20)
